Small ubiquitin‐like modifier/sentrin‐specific peptidase 1 associates with chemotherapy and is a risk factor for poor prognosis of non‐small cell lung cancer

摘要

Background SUMO /sentrin‐specific peptidase 1 ( SENP 1) was associated with radioresistance of cancer cells and was upregulated in non‐small cell lung cancer ( NSCLC ). This study was to investigate the association of SENP 1 with resistance of NSCLC tumor to chemoradiotherapy. Methods Sentrin‐specific peptidase 1 expression profile was detected using the immunohistochemistry and quantitative real‐time PCR ( qRT ‐ PCR ) analyses. The relative expression level of SENP 1 mRNA was detected using qRT ‐ PCR . The response to chemoradiotherapy was evaluated according to the Response Evaluation Criteria in Solid Tumors. Results and Conclusion When compared with adjacent non‐tumor tissues, the overexpression of SENP 1 mRNA and protein in NSCLC tumor tissues was determined using qRT ‐ PCR and immunochemistry. Based on the chemoradiotherapy response rate, we found that NSCLC patients with higher SENP 1 expression showed lower rates of complete response and higher partial and non‐response rate to chemoradiotherapy. In the overall survival analysis, we found patients with high SENP 1 expression showed significant shorter survival time compared with those with low SENP 1 expression. In the multivariate Cox regression model, we found SENP 1 overexpression, TNM stage, and lymph metastasis were independent risk factors for poor prognosis of NSCLC . SENP 1 overexpression contributed to chemoradiotherapy resistance of NSCLC . The overexpression of SENP 1 could be used as a risk factor for the poor prognosis of NSCLC.